Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 1/20 | 0.43 |
| ▸ | MAPK14 | Q16539 | 5/20 | 0.39 |
| ▸ | CYP11B2 | P19099 | 3/20 | 0.39 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.39 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.38 |
| ▸ | PLAU | P00749 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.34 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.34 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.33 |
| ▸ | BACE1 | P56817 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12365262 | 0.88 | NAMPT (0.43) | NAMPTMAPK14CYP11B2CYP11B1MRGPRX4 | |
| SCHEMBL12389598 | 0.87 | NAMPT (0.43) | NAMPTCYP11B2CYP11B1MRGPRX4PLAU | |
| SCHEMBL12365879 | 0.87 | RARA (0.39) | MAPK14PTGDR2 | |
| SCHEMBL12365090 | 0.86 | NAMPT (0.43) | NAMPTMAPK14CYP11B2CYP11B1MRGPRX4 | |
| SCHEMBL12365406 | 0.85 | MAPK14 (0.49) | MAPK14GAASMN1; SMN2PDK2 | |
| SCHEMBL12389033 | 0.85 | NAMPT (0.43) | NAMPTCYP11B2CYP11B1MRGPRX4PLAU | |
| SCHEMBL12365024 | 0.84 | RARA (0.43) | NAMPTMAPK14CYP11B2CYP11B1MRGPRX4 | |
| SCHEMBL12365832 | 0.84 | MAPK14 (0.44) | MAPK14MRGPRX4PDK2 | |
| SCHEMBL12365827 | 0.84 | CA1 (0.41) | MAPK14GAARXFP1 | |
| SCHEMBL12365331 | 0.83 | MAPK14 (0.43) | MAPK14GAASMN1; SMN2PDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110207729-A1 | BICYCLIC ACYLGUANIDINE DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2011-08-25 | — | — | US | disclosed |
| US-20110207729-A1 | BICYCLIC ACYLGUANIDINE DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2011-08-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110207729-A1 | BICYCLIC ACYLGUANIDINE DERIVATIVE | HTR5A, HTR2A, HTR1E | NAMPT 2562/4885MAPK14 3304/4885CYP11B2 707/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.